Bright Minds Biosciences closed at $20.69 on Nov 5, up 9.12%, 78.4% below its 52-week closing high. Volume of 321.3K shares was 1.21× its 20-day average (close to normal).
Split-adjusted performance: -60.2% over one month, -76.7% over six months, -59.7% over one year.
Short interest was 829.7K shares at the Oct 15 settlement, down 6.0% from the prior report (1.5% of float, 4.5 days to cover).
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain.
What is DRUG's market cap?
$204.09M, based on the Nov 5 close of $20.69.
Does Bright Minds Biosciences pay a dividend?
No regular cash dividend has been paid in the last year.
How much of DRUG is sold short?
829.7K shares, 1.5% of float, as of Oct 15, 2026.
About Bright Minds Biosciences
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
